David Andorsky

2.5k total citations
71 papers, 1.2k citations indexed

About

David Andorsky is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, David Andorsky has authored 71 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pathology and Forensic Medicine, 39 papers in Genetics and 36 papers in Oncology. Recurrent topics in David Andorsky's work include Lymphoma Diagnosis and Treatment (46 papers), Chronic Lymphocytic Leukemia Research (39 papers) and Lung Cancer Treatments and Mutations (11 papers). David Andorsky is often cited by papers focused on Lymphoma Diagnosis and Treatment (46 papers), Chronic Lymphocytic Leukemia Research (39 papers) and Lung Cancer Treatments and Mutations (11 papers). David Andorsky collaborates with scholars based in United States, Germany and France. David Andorsky's co-authors include John M. Timmerman, Reiko Yamada, Geraldine S. Pinkus, David J. Betting, Jonathan Said, Dennis P. Lund, Christopher Duggan, Denise Richardson, Sharon Collier and C. Walton Lillehei and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Consulting and Clinical Psychology.

In The Last Decade

David Andorsky

63 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Andorsky United States	15	555	397	308	264	226	71	1.2k
Lisa Argnani Italy	21	537 1.0×	948 2.4×	18 0.1×	261 1.0×	298 1.3×	120	1.4k
David E. E. Sloane United States	18	114 0.2×	156 0.4×	35 0.1×	328 1.2×	436 1.9×	39	1.6k
Neil Chua Canada	21	1.1k 1.9×	658 1.7×	13 0.0×	183 0.7×	280 1.2×	62	1.7k
David J. Straus United States	15	634 1.1×	498 1.3×	18 0.1×	48 0.2×	187 0.8×	23	1.2k
Theodoros Michelakos United States	18	755 1.4×	73 0.2×	47 0.2×	231 0.9×	32 0.1×	43	1.3k
Tracey L. O’Connor United States	17	944 1.7×	137 0.3×	15 0.0×	91 0.3×	39 0.2×	59	1.4k
Cesar Homero Gutiérrez‐Aguirre Mexico	20	232 0.4×	108 0.3×	14 0.0×	198 0.8×	267 1.2×	118	1.2k
Roberta Babare Italy	8	192 0.3×	142 0.4×	23 0.1×	57 0.2×	56 0.2×	13	597
Saling Huang United States	10	134 0.2×	52 0.1×	49 0.2×	107 0.4×	32 0.1×	14	580
Claire Bethune United Kingdom	13	37 0.1×	131 0.3×	116 0.4×	156 0.6×	388 1.7×	25	683

Countries citing papers authored by David Andorsky

Since Specialization

Citations

This map shows the geographic impact of David Andorsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Andorsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Andorsky more than expected).

Fields of papers citing papers by David Andorsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Andorsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Andorsky. The network helps show where David Andorsky may publish in the future.

Co-authorship network of co-authors of David Andorsky

This figure shows the co-authorship network connecting the top 25 collaborators of David Andorsky. A scholar is included among the top collaborators of David Andorsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Andorsky. David Andorsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jabbour, Elias, Timothy P. Hughes, Richard Van Etten, et al.. (2025). CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML. Blood. 146(Supplement 1). 901–901.

Hughes, Timothy P., Andreas Hochhaus, Naoto Takahashi, et al.. (2024). ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.. Journal of Clinical Oncology. 42(17_suppl). LBA6500–LBA6500. 2 indexed citations

Atallah, Ehab, Moshe Levy, Paul Koller, et al.. (2024). Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI). Blood. 144(Supplement 1). 479–479. 3 indexed citations

Andorsky, David, Vamsi Kota, & Kendra Sweet. (2024). Exploring treatment decision-making in chronic myeloid leukemia in chronic phase. Frontiers in Oncology. 14. 1369246–1369246. 1 indexed citations

Cortes, Jörge E., Andreas Hochhaus, Timothy P. Hughes, et al.. (2024). Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study. Blood. 144(Supplement 1). 475–475. 3 indexed citations

Arch, Joanna J., et al.. (2023). Anxiety and Depression in Metastatic Cancer: A Critical Review of Negative Impacts on Advance Care Planning and End-of-Life Decision Making With Practical Recommendations. JCO Oncology Practice. 19(12). 1097–1108. 10 indexed citations

Wang, Michael, Toby A. Eyre, Nirav N. Shah, et al.. (2023). BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.. Journal of Clinical Oncology. 41(16_suppl). TPS7587–TPS7587.

Arch, Joanna J., Jill Mitchell, Sarah J. Schmiege, et al.. (2022). A randomized controlled trial of a multi-modal palliative care intervention to promote advance care planning and psychological well-being among adults with advanced cancer: study protocol. BMC Palliative Care. 21(1). 198–198. 5 indexed citations

Lansigan, Frederick, David Andorsky, Morton Coleman, et al.. (2021). Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 812–812. 11 indexed citations

10.

Arch, Joanna J., Jill Mitchell, Charles M. Judd, et al.. (2021). Randomized trial of acceptance and commitment therapy for anxious cancer survivors in community clinics: Outcomes and moderators.. Journal of Consulting and Clinical Psychology. 89(4). 327–340. 29 indexed citations

11.

Arch, Joanna J., Joel N. Fishbein, Jill Mitchell, et al.. (2020). Acceptability, Feasibility, and Efficacy Potential of a Multimodal Acceptance and Commitment Therapy Intervention to Address Psychosocial and Advance Care Planning Needs among Anxious and Depressed Adults with Metastatic Cancer. Journal of Palliative Medicine. 23(10). 1380–1385. 27 indexed citations

12.

Andorsky, David, et al.. (2019). Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting. Blood. 134(Supplement_1). 2810–2810. 2 indexed citations

13.

Sharman, Jeff P., et al.. (2018). Treatment Patterns and Outcomes of 159 Ibrutinib-Treated MCL Patients in the United States: A Retrospective Electronic Medical Record Database and Chart Review Study. Blood. 132(Supplement 1). 4163–4163. 3 indexed citations

14.

Georgiev, Pencho, David Belada, Shaker R. Dakhil, et al.. (2016). Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma. Annals of Oncology. 27. vi324–vi324.

15.

Timmerman, John M., John C. Byrd, David Andorsky, et al.. (2012). A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. Clinical Cancer Research. 18(20). 5752–5760. 53 indexed citations

16.

Andorsky, David, Reiko Yamada, Jonathan Said, et al.. (2011). Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells. Clinical Cancer Research. 17(13). 4232–4244. 267 indexed citations

17.

Andorsky, David, Mitchell B. Cohen, Arash Naeim, & Lauren Pinter‐Brown. (2010). Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplantation. 46(9). 1219–1225. 22 indexed citations

18.

Andorsky, David & John M. Timmerman. (2008). Interleukin-21: biology and application to cancer therapy. Expert Opinion on Biological Therapy. 8(9). 1295–1307. 35 indexed citations

19.

Andorsky, David, Fausto R. Loberiza, & S J Lee. (2006). Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation. Bone Marrow Transplantation. 37(9). 889–895. 39 indexed citations

20.

Goldhaber‐Fiebert, Jeremy D., Sara N. Goldhaber-Fiebert, & David Andorsky. (2004). Male involvement in cardiovascular preventive healthcare in two rural Costa Rican communities. Preventive Medicine. 40(6). 690–695. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact